ELI LILLY (LLY)
The company announced that it plans to make available on the market 20 new drugs in the coming years, with even the possibility of seeing approved new indications for products already authorized. The therapeutic areas in which the company is engaged are diabetes, oncology, immunology, neurodegeneration and pain therapy.
P/E 34.41
Forward P/E 18.90
Yeld: 2.72%
P/E 34.41
Forward P/E 18.90
Yeld: 2.72%
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.